IL-17 Inhibition in Axial Spondyloarthritis

Il-17 Inhibition: Emerging Perspectives in the Future Management of Axial Spondyloarthritis

Disclosure: Atul Deodhar has participated in advisory boards and received research grants from AbbVie, Amgen, Janssen, Novartis, Pfizer, and UCB. Dirk Elewaut has received a research grant, consultation fees, and speaker honoraria from AbbVie, Boehringer Ingelheim, BMS, and Merck. Dominique Baeten has received consultation fees from AbbVie, Pfizer, MSD, UCB, Janssen, Novartis, Eli Lilly, Boehri...

IL-17 in spondyloarthritis: is the T-party over?

The past decade has witnessed significant progress in revealing an important role for IL-17 in the pathogenesis of several immune-mediated inflammatory diseases. Recent studies have provided new insights into the cellular source of IL-17, originally identified as the signature cytokine of a distinct CD4(+) T-cell subset known as Th17. Accumulating evidence suggests that the majority of the IL-1...

Epidemiology of axial spondyloarthritis

Cytokine profiles in axial spondyloarthritis

OBJECTIVES Current studies concentrate on the cytokine network and its role in the pathogenesis of spondyloarthritis (SpA). In this study, we analyzed whether the serum cytokine profile (interleukins: IL-10, IL-11, IL-12, IL-15, IL-17, IL-23 and IL-33) correlates with demographic data, clinical manifestations, disease activity and treatment outcome in a group of patients with axial spondyloarth...

Axial Spondyloarthritis and Cigarette Smoking

BACKGROUND Smoking is one of the main environmental risk factors involved in several rheumatic diseases according to ACR 2014, it is included among the risk factors for severe axial spondyloarthritis. OBJECTIVES The objective is to study the association between smoking and the activity of the disease, the functional impact and the severity of the axial spondyloarthritis. METHODS It is a tra...